- Home
- LAB vs ABVX Comparison
LAB vs ABVX Comparison
Compare LAB & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- ABVX
- Stock Information
- Founded
- LAB 1999
- ABVX 2013
- Country
- LAB United States
- ABVX France
- Employees
- LAB N/A
- ABVX N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- ABVX
- Sector
- LAB Industrials
- ABVX
- Exchange
- LAB Nasdaq
- ABVX Nasdaq
- Market Cap
- LAB 435.8M
- ABVX 378.7M
- IPO Year
- LAB 2011
- ABVX N/A
- Fundamental
- Price
- LAB $1.24
- ABVX $6.77
- Analyst Decision
- LAB Buy
- ABVX Strong Buy
- Analyst Count
- LAB 2
- ABVX 7
- Target Price
- LAB $2.50
- ABVX $37.29
- AVG Volume (30 Days)
- LAB 1.2M
- ABVX 163.1K
- Earning Date
- LAB 05-06-2025
- ABVX 03-24-2025
- Dividend Yield
- LAB N/A
- ABVX N/A
- EPS Growth
- LAB N/A
- ABVX N/A
- EPS
- LAB N/A
- ABVX N/A
- Revenue
- LAB $174,432,000.00
- ABVX $11,172,999.00
- Revenue This Year
- LAB N/A
- ABVX $371.31
- Revenue Next Year
- LAB $12.77
- ABVX N/A
- P/E Ratio
- LAB N/A
- ABVX N/A
- Revenue Growth
- LAB 64.03
- ABVX 135.94
- 52 Week Low
- LAB $0.97
- ABVX $4.77
- 52 Week High
- LAB $2.74
- ABVX $16.63
- Technical
- Relative Strength Index (RSI)
- LAB 56.32
- ABVX 57.33
- Support Level
- LAB $0.99
- ABVX $5.89
- Resistance Level
- LAB $1.18
- ABVX $6.75
- Average True Range (ATR)
- LAB 0.09
- ABVX 0.65
- MACD
- LAB 0.02
- ABVX 0.13
- Stochastic Oscillator
- LAB 75.00
- ABVX 62.34
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.